Vertex Pharmaceuticals Inc Stock Crash

The Shares of Vertex Pharmaceuticals Inc. inched 0.05% higher to $213.00 Tuesday. This proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.87% to 4,152.10 and Dow Jones Industrial Average DJIA falling 1.36% to 34,269.16.

Vertex Pharmaceuticals Inc. closed $93.08 below its 52-week high ($306.08), which the company reached on July 7th. The stock outperformed some of its competitors Tuesday, as Johnson & Johnson JNJ fell 0.82% to $168.88, Merck & Co. Inc. MRK fell 0.91% to $77.46, and AbbVie Inc. ABBV fell 1.14% to $114.89. Trading volume (1.3 M) remained 364,597 below its 50-day average volume of 1.7 M.

Investment analysts at Cantor Fitzgerald issued their FY2022 earnings estimates for Vertex Pharmaceuticals in a report issued on May 5th by Cantor Fitzgerald analysts. The analysts expect that the pharmaceutical company will earn $8.49 per share for the year. Vertex Pharmaceuticals Inc announced its quarterly earnings results on April 29th. The pharmaceutical company reported $2.98 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.38 by $0.60.

 The Pharmaceuticals had a net margin of 38.51% and a return on equity of 28.55%. The company traded up $1.98 during mid-day trading on Friday, hitting $215.14. 16,852 shares of the company’s stock were exchanged, compared to its average volume of 1,952,535. Vertex Pharmaceuticals has a one year low of $202.57 and a one year high of $306.08.